Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.50 |
| ▸ | F10 | P00742 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27883894 | 0.98 | MAPT (0.50) | MAPTKDM4EGAABLMAKR1C3 | |
| SCHEMBL85229 | 0.91 | MAPT (0.49) | MAPTKDM4EGAABLMAKR1C3 | |
| SCHEMBL11934590 | 0.85 | MAPT (0.43) | MAPTKDM4EGAABLMAKR1C3 | |
| SCHEMBL11934575 | 0.85 | MAPT (0.44) | MAPTKDM4EGAABLMAKR1C3 | |
| SCHEMBL11934576 | 0.85 | MAPT (0.49) | MAPTKDM4EGAABLMAKR1C3 | |
| SCHEMBL1629441 | 0.82 | HPN (0.49) | MAPTKDM4EALDH1A1KMT2APOLB | |
| SCHEMBL29740648 | 0.82 | HPN (0.49) | MAPTKDM4EALDH1A1KMT2APOLB | |
| SCHEMBL14295992 | 0.82 | MAPT (0.50) | MAPTF10PTGS2LMNAKMT2A | |
| SCHEMBL28005757 | 0.81 | PTGS2 (0.54) | F10PTGS2 | |
| SCHEMBL4431776 | 0.79 | MEN1 (0.36) | MAPTKDM4EGAABLMAKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 331 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115825264-A | Method for detecting 4- (4-nitrophenyl) -3-morpholinone in soil and water by using HPLC | 贵州健安德科技有限公司 | 2023-03-21 | — | — | CN | claimed |
| CN-111721858-B | Method for determining genotoxic impurities in rivaroxaban | 杭州华东医药集团新药研究院有限公司 | 2022-07-01 | — | — | CN | claimed |
| EP-3737671-B1 | PROCESS FOR THE PREPARATION OF 4-(4-AMINOPHENYL)MORPHOLIN-3-ONE | RICHTER GEDEON NYRT (HU) | 2021-11-17 | — | — | EP | claimed |
| EP-3737671-A1 | PROCESS FOR THE PREPARATION OF 4-(4-AMINOPHENYL)MORPHOLIN-3-ONE | Richter Gedeon Nyrt. (HU) | 2020-11-18 | — | — | EP | claimed |
| CN-109384738-B | Preparation method of 4- (4-aminophenyl) morpholine-3-one | 新发药业有限公司 | 2020-10-02 | — | — | CN | claimed |
| CN-111721858-A | Method for determining genotoxic impurities in rivaroxaban | 杭州华东医药集团新药研究院有限公司 | 2020-09-29 | — | — | CN | claimed |
| CN-104860936-A | Rivaroxaban preparation method | ZHEJIANG TIANSHUN BIOTECHNOLOGY CO LTD | 2015-08-26 | — | — | CN | claimed |
| CN-104829551-A | Method for preparing rivaroxaban midbody 4-(4-aminophenyl)-3-morpholone | ZHEJIANG TIANSHUN BIOTECHNOLOGY CO LTD | 2015-08-12 | — | — | CN | claimed |
| CN-104788444-A | Preparation method of rivaroxaban | ZHEJIANG TIANSHUN BIOTECHNOLOGY CO LTD | 2015-07-22 | — | — | CN | claimed |
| EP-1664004-B1 | METHOD FOR THE PRODUCTION OF 4-(4-AMINOPHENYL)-3-MORPHOLINON | BAYER IP GMBH (DE) | 2015-06-24 | — | — | EP | claimed |
| US-20070066611-A1 | Method for the production of 4-(4-aminophenyl)-3-morpholinone | BAYER HEALTHCARE AG (DE) | 2007-03-22 | — | — | US | claimed |
| JP-2007501818-A | — | — | 2007-02-01 | — | — | JP | claimed |
| EP-1654240-B1 | METHOD FOR PRODUCTION OF N-ARYL MORPHOLINONES | MERCK PATENT GMBH (DE) | 2006-11-02 | — | — | EP | claimed |
| CN-1852902-A | Process for preparing 4- (4-aminophenyl) -3-morpholinone | BAYER HEALTHCARE AG (DE) | 2006-10-25 | — | — | CN | claimed |
| US-20060217550-A1 | One pot process; cyclization; 4-(4-nitrophenyl)-3-oxomorpholine; Factor Xa inhibitors; , myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty and claudicatio intermittens | MERCK PATENT GMBH (DE) | 2006-09-28 | — | — | US | claimed |
| CN-1832933-A | Method for production of n-aryl morpholinones | MERCK PATENT GMBH (DE) | 2006-09-13 | — | — | CN | claimed |
| EP-1664004-A1 | METHOD FOR THE PRODUCTION OF 4-(4-AMINOPHENYL)-3-MORPHOLINON | Bayer HealthCare AG (DE) | 2006-06-07 | — | — | EP | claimed |
| EP-1654240-A1 | METHOD FOR PRODUCTION OF N-ARYL MORPHOLINONES | MERCK PATENT GmbH (DE) | 2006-05-10 | — | — | EP | claimed |
| WO-2005026135-A1 | METHOD FOR THE PRODUCTION OF 4-(4-AMINOPHENYL)-3-MORPHOLINON | BAYER HEALTHCARE AG (DE) | 2005-03-24 | — | — | WO | claimed |
| WO-2005016899-A1 | METHOD FOR PRODUCTION OF N-ARYL MORPHOLINONES | MERCK PATENT GMBH (DE) | 2005-02-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066611-A1 | Method for the production of 4-(4-aminophenyl)-3-morpholinone | ADH5, ADH1C, ADH1A | MAPT 2570/4885KDM4E 531/4885GAA 3130/4885 |
| US-20060217550-A1 | One pot process; cyclization; 4-(4-nitrophenyl)-3-oxomorpholine; Factor Xa inhibitors; , myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty and claudicatio intermittens | PLAT, PCSK9, SERPINE1 | MAPT 4446/4885KDM4E 4155/4885GAA 2907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.